#124849
Re: Farmas USA
ARQT
Offering a 25$, orbimed compra 500.000 acciones, que añade a su posición de 560.000 acciones que tenia a 17$ de la IPO
Hacen una crema para psoriasis, en fase 3, dicen que es un 25-300x veces más efectiva que los tratamientos que hay, y que a diferencia de ellos que son esteroides, el suyo no tiene esteroides con la ventaja que eso conlleva para una enfermedad crónica ( no usar esteroides) y más segura y tolerable.
Offering a 25$, orbimed compra 500.000 acciones, que añade a su posición de 560.000 acciones que tenia a 17$ de la IPO
Hacen una crema para psoriasis, en fase 3, dicen que es un 25-300x veces más efectiva que los tratamientos que hay, y que a diferencia de ellos que son esteroides, el suyo no tiene esteroides con la ventaja que eso conlleva para una enfermedad crónica ( no usar esteroides) y más segura y tolerable.
Topical roflumilast cream (ARQ-151) is a small molecule inhibitor of phosphodiesterase type 4 (PDE4), an intracellular enzyme that increases the production of proinflammatory mediators and decreases production of anti-inflammatory mediators, and has been implicated in a wide range of inflammatory diseases including psoriasis, eczema, and chronic obstructive pulmonary disease (COPD). PDE4 is an established target in dermatology, and other PDE4 inhibitors have been approved by the FDA for the topical or systemic treatment of plaque psoriasis and atopic dermatitis. Topical roflumilast cream is a highly potent, selective PDE4 inhibitor in a convenient, once-daily formulation that Arcutis is developing for chronic plaque psoriasis and atopic dermatitis. Roflumilast is 25–300X more potent than the two other FDA-approved PDE4 inhibitors used in dermatology and has a well-established safety profile with more than 1 million patient years of exposure in clinical use.
In our plaque psoriasis development program, we have completed a 332-patient Phase 2b study and an 89-patient Phase 2a study of topical roflumilast cream. In the recent Phase 2b study, topical roflumilast cream produced statistically significant reductions compared to vehicle in the signs of plaque psoriasis, and also demonstrated excellent safety and tolerability in this population. We also recently completed two pivotal Phase 3 studies of topical roflumilast cream in plaque psoriasis, and expect to release data from those trials in Q1 2021.
